Core Viewpoint - Hansoh Pharmaceutical (03692) announced that its innovative drug, XinYue® (Inalizumab Injection), received a drug registration certificate from the National Medical Products Administration (NMPA) of China on August 26, 2025, for an additional indication: treatment of adult patients with Immunoglobulin G4-related disease (IgG4-RD) [1] Summary by Categories Product Approval - XinYue® has been approved for a second indication, expanding its therapeutic use [1] - The new indication was included in the NMPA's priority review and approval process on February 8, 2025 [1]